DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA.
The generic ingredient in LICART is diclofenac epolamine. There are forty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the diclofenac epolamine profile page.
Generic Entry Opportunity Date for LICART
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Ibsa Inst Bio||LICART||diclofenac epolamine||SYSTEM;TOPICAL||206976-001||Dec 19, 2018||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|